Opinion/decision on a Paediatric investigation plan (PIP): Efavaleukin alfa, decision type: , therapeutic area: , PIP number: P/0432/2022

Human medicines European public assessment report (EPAR): Cholib, fenofibrate,simvastatin, Dyslipidemias, Date of authorisation: 26/08/2013, Revision: 16, Status: Authorised

Focus group on veterinary pharmacovigilance reporting in poultry, European Medicines Agency, from 11/10/2023 to 11/10/2023

Opinion/decision on a Paediatric investigation plan (PIP): Odronextamab, decision type: , therapeutic area: , PIP number: P/0426/2022

Human medicines European public assessment report (EPAR): Zarzio, filgrastim, Neutropenia;Hematopoietic Stem Cell Transplantation;Cancer, Date of authorisation: 06/02/2009, Revision: 24, Status: Authorised

Human medicines European public assessment report (EPAR): Adrovance, alendronic acid,colecalciferol, Osteoporosis, Postmenopausal, Date of authorisation: 04/01/2007, Revision: 25, Status: Authorised

Human medicines European public assessment report (EPAR): Ovitrelle, choriogonadotropin alfa, Anovulation;Reproductive Techniques, Assisted;Infertility, Female, Date of authorisation: 02/02/2001, Revision: 22, Status: Authorised

Human medicines European public assessment report (EPAR): CellCept, mycophenolate mofetil, Graft Rejection, Date of authorisation: 14/02/1996, Revision: 38, Status: Authorised

Human medicines European public assessment report (EPAR): Lixiana, edoxaban, Stroke;Venous Thromboembolism, Date of authorisation: 19/06/2015, Revision: 18, Status: Authorised

Human medicines European public assessment report (EPAR): Roteas, edoxaban, Stroke;Venous Thromboembolism, Date of authorisation: 19/04/2017, Revision: 11, Status: Authorised